Please use this identifier to cite or link to this item:
|Title:||Anticoagulation and monitoring of a novel and reversible factor IXa inhibitor||Authors:||Becker, R.C.
|Issue Date:||Dec-2013||Citation:||Becker, R.C., Chan, M.Y., Vavalle, J.P., Povsic, T.J. (2013-12). Anticoagulation and monitoring of a novel and reversible factor IXa inhibitor. Drug Development Research 74 (8) : 510-516. ScholarBank@NUS Repository. https://doi.org/10.1002/ddr.21109||Abstract:||Clinical Development Phases I-III Regulatory, Quality, Manufacturing Thrombosis as a clinical phenotype is ubiquitous in human diseases and conditions, ranging from atherosclerosis and other vascular disorders to trauma, surgery, malignancy, infections, blood dyscrasias, auto-immunity, and complications of pregnancy. While each condition carries its own distinct signature and predisposition for thrombosis as a nonphysiological event, there are several common themes that center on cellular and noncellular elements, including well-characterized coagulation proteases. Over the past decade, our group has been actively involved with the development of a factor IXa inhibitor, pegnivacogin, and its complementary antidote or control agent, anivamersen. The following review provides a summary of fundamental constructs, milestones, and the current status of our translational journey. © 2013 Wiley Periodicals, Inc.||Source Title:||Drug Development Research||URI:||http://scholarbank.nus.edu.sg/handle/10635/126917||ISSN:||02724391||DOI:||10.1002/ddr.21109|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Oct 15, 2019
checked on Oct 11, 2019
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.